Recent Updates
Recently added Catalysts

EXS73565

Phase 1

Relapsed or Refractory B-cell Malignancies | Small molecule | Other |Recursion Pharmaceuticals, Inc.|Last Updated: Dec 3, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDDMC
Total Trials1
Total Enrollment50
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06980116Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell MalignanciesPHASE1 RECRUITING 50 — — Mar 31, 2025Dec 1, 2028Dec 3, 20254 Spain, United Kingdom
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Up to 282 days
Dose-limiting toxicities (DLTs) of EXS73565-001
Up to 21 days
Secondary Endpoints
Time to Maximum Concentration (Tmax) of EXS73565-001
Up to 253 days
Area Under the Concentration-time Curve from Time Zero to the Time of the Last Quantifiable Concentration AUC(0-last) of EXS73565-001
Up to 253 days
Maximum Concentration (Cmax) of EXS73565-001
Up to 253 days
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
EXS73565EXPERIMENTAL -
Interventions
NameTypeDescription
EXS73565DRUGEXS73565 oral administration
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites4

Key Inclusion Criteria: * Age ≥18 years at the time of signing the informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Histologically confirmed diagnosis of one of the following B-cell malignancies: chronic lymphocytic leukemia (CLL), including Richter's trans...

Countries:SpainUnited Kingdom
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06980116primaryCompletionDate: changed
LOWMay 24, 2026NCT06980116studyFirstPostDate: changed